摘要
目的:观察聚乙二醇干扰素(PEG-IFN)α-2a联合利巴韦林治疗转氨酶持续正常的慢性丙型肝炎(CHC)远期疗效。方法:选择68例丙氨酸转移酶(ALT)持续正常CHC患者为观察组,50例ALT升高的CHC患者为对照组,均接受PEG-IFNα-2a每周一次皮下注射,同时口服利巴韦林,HCVRNA基因型为1b或未分出型者疗程为48周,基因为2a型者疗程24周。两组患者均随访至停药后3年,内容包括持续病毒学应答、生化应答、影像学改变及生存质量评估。观察组和对照组分别有51例和40例完成3年随访。结果:随访至3年末,观察组和对照组患者均获得相似的较高持续病毒学应答率(80.4%vs80.0%,P=1.000),随访1年末时获得持续病毒学应答(SVR)的病例在后2年的随访中无一例复发。取得SVR的患者均保持了持续生化学应答和影像学稳定,同时两组患者生存质量也得到提高,尤其是社会功能、活力、总健康状况、情绪角色及心理健康5个领域改善明显。两组间比较无统计学差异(P>0.05)。结论:PEG-IFNα-2a联合利巴韦林治疗转氨酶持续正常的慢性丙型肝炎可取得与ALT升高者相似的远期疗效。
Objective To study the prostecdtive efficacy of peginterferon-alpha 2a （PEG-IFN） combined with ribavirin on chronic hepatitis C （CHC） patients with persistently normal aminotransferase levels. Methods 68 patients with persistently normal aminotransferase levels were included as observe group, and 50 patients with elevated aminotransferase levels were included as control group. Both groups received PEG-IFN subcutaneous injection weekly combined with ribavirin taken orally, and were followed up for 3 years to test the virologic response, biochemical response, imageologic changes, and quality of life. Results 51 cases in observe group and 40 cases in control group were followed up for 3 years. The final sustained virologic response （SVR） in the two groups were 80.4% and 80.0%, respectively （P = 1.000）. The cases with SVR at the end of 1 year follow-up had no virologic relapse in the following 2 years. Patients with SVR maintained sustained biochemical response, stable imageologic changes, and improved quality of life, especially in society function, energy, total health status, emotion role and psychological health. There is no significant difference between the two groups （P〉 0.05）. Conclusion Prostecdtive efficacy of PEG-IFN combined with ribavirin in CHC patients with persistently normal aminotransferase levels is similar to that in patients with elevated aminotransferase levels.
出处
《实用医学杂志》
CAS
北大核心
2009年第21期3667-3669,共3页
The Journal of Practical Medicine
